The semaglutide-based treatment from Novo Nordisk competes directly with Mounjaro in the global market for type 2 diabetes care. This data compares the long-term safety and efficacy of continuing a specific dose escalation strategy within the Ozempic line against a complete switch to a rival tirzepatide therapy.
Wednesday, October 21, 2026
Story
Novo's Ozempic 2 mg Lowers Heart Risk 6% More Than Mounjaro
Business22 days ago
Patients with type 2 diabetes showed improved cardiovascular outcomes when remaining on Novo Nordisk's primary weight-loss and diabetes drug instead of transitioning to a competitor's product. A real-world study presented at the European Association for the Study of Diabetes found that adults who increased their Ozempic dose to 2 mg from 1 mg had a 6% lower risk of death, heart attack, and stroke than those who switched to Eli Lilly's Mounjaro.
Looking for more context or analysis?
Tilt chat provides reliable, tailored insights, alerts, and automations.